You have 9 free searches left this month | for more free features.

Cell therapy

Showing 9951 - 9975 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Richter Transformation Trial in Austria, Denmark, Germany (Tislelizumab, Zanubrutinib)

Recruiting
  • Richter Transformation
  • Vienna, Austria
  • +11 more
Mar 8, 2022

Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, Burkitts Lymphoma Trial in Providence (cellular immunotherapy)

Terminated
  • Mantle Cell Lymphoma
  • +4 more
  • cellular immunotherapy
  • Providence, Rhode Island
  • +1 more
Feb 23, 2022

Tissue-specific Insulin Resistance in Obstructive Sleep Apnea:

Recruiting
  • Obstructive Sleep Apnea
  • +2 more
  • Continuous Positive Airway Pressure
  • San Francisco, California
    University of California San Francisco
Sep 20, 2022

Ulcerative Colitis Flare Trial (MitoQ, Placebo)

Not yet recruiting
  • Ulcerative Colitis Flare
  • MitoQ
  • Placebo
  • (no location specified)
Oct 5, 2021

Diabetes, Type 2 Trial in Beijing (SAL067, Placebo)

Completed
  • Diabetes Mellitus, Type 2
  • Beijing, Beijing, China
    Peking University Hospital
Mar 24, 2023

Allogeneic SCT for CML, TKI Failure After TKI Failure

Unknown status
  • Chronic Myeloid Leukemia
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Oct 29, 2020

    Systemic Lupus Erythematosus Trial (Telitacicept, Hydroxychloroquine, Prednisone)

    Not yet recruiting
    • Systemic Lupus Erythematosus
    • Telitacicept
    • +6 more
    • (no location specified)
    Dec 28, 2022

    Pediatric Cancer, Sleep Trial in Battalgazi (Aromatherapy, music concert)

    Active, not recruiting
    • Pediatric Cancer
    • Sleep
    • Aromatherapy
    • music concert
    • Battalgazi, Malatya, Turkey
      Inonu University
    Dec 16, 2021

    Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Middletown, New Jersey
    • +5 more
    Aug 17, 2023

    Retention Rate of Acalabrutinib in a Non-interventional Setting

    Recruiting
    • Chronic Lymphocytic Leukaemia (CLL)
      • Zittau, Germany
        Research Site
      Jan 12, 2023

      Extensive Stage Small Cell Lung Cancer (ES-SCLC) Trial (HS-20093)

      Not yet recruiting
      • Extensive Stage Small Cell Lung Cancer (ES-SCLC)
      • (no location specified)
      Sep 19, 2023

      Role of HIV-1 Tat Protein and Anti-Tat Immune Response In HIV

      Recruiting
      • HIV/AIDS
      • No intervention
      • Rome, Italy
        Infectious Dermatology STI Unit San Gallicano Dermatologic Insti
      Mar 23, 2022

      First-Line Serplulimab Plus Chemotherapy in Treatment of

      Not yet recruiting
      • Lung Cancer
      • Serplulimab plus chemotherapy
      • (no location specified)
      May 16, 2023

      Complications and Recurrences After Mohs Micrographic Surgery

      Recruiting
      • Skin Cancer
      • +9 more
      • Mohs surgery
      • Slow Mohs surgery
      • Maastricht, Netherlands
        Maastricht University Medical Center+
      Aug 23, 2023

      Infection, Human Immunodeficiency Virus, HIV, Arthralgia Trial in Orel, St. Petersburg, Madrid (DTG 50 mg /ABC 600 mg /3TC 300

      Completed
      • Infection, Human Immunodeficiency Virus
      • +2 more
      • DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
      • Orel, Russian Federation
      • +2 more
      Sep 9, 2022

      Acute Myeloid Leukemia Trial (Sulfasalazine)

      Not yet recruiting
      • Acute Myeloid Leukemia
      • (no location specified)
      Oct 11, 2022

      Cardiovascular Diseases, CHF, Dilated Cardiomyopathy Trial in Nanjing (hiPSC-CM therapy)

      Recruiting
      • Cardiovascular Diseases
      • +2 more
      • hiPSC-CM therapy
      • Nanjing, Jiangsu, China
        Help Therapeutics
      Mar 24, 2022

      ALL Ph Positive Trial in Italy (Total therapy approach)

      Active, not recruiting
      • ALL Ph Positive
      • Total therapy approach
      • Rionero in Vulture, Potenza, Italy
      • +50 more
      Oct 7, 2020

      Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer Trial in London (Palbociclib, Avelumab)

      Recruiting
      • Triple Negative Breast Cancer
      • +5 more
      • Manchester, Greater Manchester, United Kingdom
      • +6 more
      Jan 5, 2023

      Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

      Recruiting
      • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
      • Houston, Texas
        M D Anderson Cancer Center
      Feb 1, 2022

      Locally Advanced Head and Neck Squamous Cell Carcinoma Trial in Columbus (Counseling, Dietary Counseling and Surveillance,

      Active, not recruiting
      • Locally Advanced Head and Neck Squamous Cell Carcinoma
      • Counseling
      • +4 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Jan 5, 2023

      Coronary Artery Disease, Atherosclerosis of Coronary Artery Trial in Nijmegen (Evolocumab 140 MG/ML [Repatha])

      Recruiting
      • Coronary Artery Disease
      • Atherosclerosis of Coronary Artery
      • Evolocumab 140 MG/ML [Repatha]
      • Nijmegen, Gelderland, Netherlands
        Radboud University Medical Center
      Jan 11, 2022

      Oncology, Neuroendocrine Carcinoma Trial in United Kingdom (Liposomal Irinotecan, Fluorouracil, Folinic Acid)

      Active, not recruiting
      • Oncology
      • Neuroendocrine Carcinoma
      • Liposomal Irinotecan
      • +3 more
      • Glasgow, United Kingdom
      • +3 more
      Dec 2, 2022

      Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Worldwide (procedure,

      Active, not recruiting
      • Acute Lymphoblastic Leukemia
      • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
      • Allogeneic Hematopoietic Stem Cell Transplantation
      • +15 more
      • Birmingham, Alabama
      • +550 more
      Jan 28, 2023